Hollis-Eden Pharmaceuticals, Inc.
Pharmaceutical firm reports loss of $0.35 per share
Published in Lab Law Weekly, June 10th, 2005
For the quarter ended March 31, 2005, the company reported a net loss of $6.8 million (or $0.35 per share), compared to a net loss of $5.9 million (or $0.31 per share) in the first quarter of 2004.
Research and development expenses for the first quarter of 2005 totaled $5.3 million, compared to $4.7 million in the first quarter of 2004. The increase in research and development expenses in the first quarter of 2005 was due mainly to the growth in the company's laboratory operations, preclinical activities and personnel associated with advancing the...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Law Weekly
Source: Lab Law Weekly (2005-06-10)
More Articles from Lab Law Weekly
- Ciphergen Biosystems, Inc.
ProteinChip System developer reports financial results for first-quarter 2005 - GenVault Corp.
Company gets rights to DNA labeling technology - Genitope Corp.
H. David Miller named VP of information technology and legal affairs - Heska Corporation
Diagnostics company announces 200th U.S. patent issued - LMA International NV
Designer of laryngeal mask files court action for patent infringement in Germany - Linguagen Corp.
Flavor-focused company forms scientific advisory board to further taste research - More from this issue of Lab Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
